tislelizumab

San Carlos, Calif. – August 31, 2026 BeOne Medicines announced new Phase 3 overall survival data from the HERIZON-GEA-01...

Dublin, Ireland, August 25, 2026 Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved two...

SAN CARLOS, Calif., August 25, 2026 BeOne Medicines Ltd. announced that the U.S. Food and Drug Administration (FDA) has...

NANJING, China — August 25, 2026 Leads Biolabs announced that its proprietary Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has...

CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...

SAN CARLOS, CALIFORNIA, April 29, 2026 BeOne Medicines has announced that the U.S. Food and Drug Administration (FDA) has...